Page 364 - Read Online

Page 6 of 9 Nedogoda et al. Vessel Plus 2018;2:37 I http://dx.doi.org/10.20517/2574-1209.2018.36

Table 5. Changes in the studied biochemical indicators after 6 months
Indicator Initially 6 months
TC, mmol/L 6.4 ± 1.0 4.5 ± 1.0*
HDL, mmol/L 1.2 ± 0.3 1.3 ± 0.3*
TG, mmol/L 2.5 ± 0.7 1.7 ± 0.5*
LDL, mmol/L 4.1 ± 1.1 2.5 ± 1.1*
ALT, u/L 27.9 ± 10.8 24.8 ± 7.8
AST, u/L 29.3 ± 8.1 24.3 ± 6.8
Creatinine, μmol/L 81.6 ± 9.5 72.7 ± 8.3
*P < 0.05 vs. baseline; TC: total cholesterol; HDL: high-density lipoproteins; TG: triglycerids; LDL: low-density lipoproteins; ALT: alanine
transaminase; AST: aspartate aminotransferase

Table 6. Changes in the indicators of carbohydrate metabolism after 6 months
Indicator Initially 6 months
Fasting plasma glucose, mmol/L 7.0 ± 1.3 6.2 ± 1.0*
Insulin, μIU/mL 15.5 ± 5.9 13.8 ± 6.3*
HOMA index, μIU/mL 4.8 ± 2.1 3.7 ± 1.5*

*P < 0.05 vs. Baseline; HOMA: homeostasis model assessment

Table 7. Trends in the adipokin levels after 6 months
Indicator Initially 12 weeks
Leptin, ng/mL 16.3 ± 7.7 14.6 ± 7.9*
Adiponectin, μg/mL 6.9 ± 2.6 7.6 ± 2.8*
us-CRP, mg/L 3.1 ± 1.6 2.7 ± 1.5*
*P < 0.05 vs. baseline; us-CRP: ultra-sensitive C-reactive protein

Table 8. Changes in the anthropometric indicators after 6 months
Indicator Initially 6 months
Weight, kg 82.8 ± 9.2 81.6 ± 8.4
BMI, kg/m 2 28.8 ± 3.5 28.4 ± 3.4
WC, cm 86.9 ± 13.0 83.1 ± 11.5
HC, cm 104.1 ± 13.6 100.1 ± 13.5
Body fat % 38.7 ± 7.7 37.7 ± 8.2
BMI: body mass index; WC: waist circumference; HC: hip circumference

accompanied by an improvement in the carbohydrate metabolism indicators [Table 6]: a decrease of 11.1 %
in the insulin (P < 0.05) and 22.9% in the HOMA index (P < 0.05).

Particular attention should be paid to the possibility of the fixed-dose combination of lisinopril +
amlodipine + rosuvastatin to have a positive effect on the level of key adipokines: the average leptin level
has become lower by 10.7% (P < 0.05), us-CRP - by 11.8% (P < 0.05) and the adiponectin level has increased
by 9.9% (P < 0.05) [Table 7].

There have been no statistically significant changes in the anthropometric indicators revealed during the
study [Table 8].

DISCUSSION
The importance of assessing the possibility of further angioprotection with the use of the fixed-dose
combination of lisinopril + amlodipine + rosuvastatin in patients with AH undergoing a two-component